Dipeptidyl peptidase-4 inhibitors use in clinical practice
- Authors: Morgunova T.B.1, Fadeyev V.V.1
-
Affiliations:
- I.M.Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 21, No 4 (2019)
- Pages: 40-44
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/96817
- DOI: https://doi.org/10.26442/20751753.2019.4.190349
- ID: 96817
Cite item
Full Text
Abstract
According to modern view treatment of patients with diabetes mellitus is aimed not only at reaching target glycemic control levels but also at preventing development and progressing of late diabetes mellitus complications, improvement of quality of life and increase of life expectancy of patients. The relevance of the diabetes treatment research is explained with growing disorder prevalence including its prevalence in older population. Over the last years new classes of antihyperglycemic medications came into use: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 agonists, and sodium-glucose linked transporter-2 inhibitors. Long-term experience of DPP-4 inhibitors use allows to conclude not only of effectiveness of medications of this class but also of their safety. Several studies of DPP-4 inhibitors use in older patients with comorbid disorders and renal impairment have been conducted including studies in real clinical practice. Results of studies of cardiovascular safety of medications from DPP-4 inhibitors class in patients with diabetes mellitus type 2 have been published. The article discusses the issues of antihyperglycemic therapy choice and the place of DPP-4 inhibitors in clinical practice.
Full Text
##article.viewOnOriginalSite##About the authors
Tatiana B. Morgunova
I.M.Sechenov First Moscow State Medical University (Sechenov University)
Email: tanmorgun@mail
Cand. Sci. (Med.)
Valentin V. Fadeyev
I.M.Sechenov First Moscow State Medical University (Sechenov University)Corr. Memb. RAS, D. Sci. (Med.), Full Prof.
References
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 8-й вып. Сахарный диабет. 2017; 20 (1S): 1-112. doi: 10.14341/DM20171S8
- Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19 (2): 104-12. doi: 10.14341/DM2004116-17
- Montvida O, Shaw J, Atherton J.J et al. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care 2018; 41 (1): 69-78. doi: 10.2337/dc17-1414
- Overbeek J.A, Heintjes E.M, Prieto-Alhambra D et al. Type 2 Diabetes Mellitus Treatment Patterns Across Europe: A Population-based Multi-database Study. Clin Ther 2017; 39 (4): 759-70. doi: 10.1016/j.clinthera.2017.02.008
- Wilkinson S, Douglas I.J, Williamson E et al. Factors associated with choice of intensification treatment for type 2 diabetes after metformin monotherapy: a cohort study in UK primary care. Clin Epidemiol 2018; 10: 1639-48. doi: 10.2147/CLEP.S176142. eCollection 2018.
- Davies M.J, D'Alessio D.A, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018; 41 (12): 2669-701. doi: 10.2337/dci18-0033
- Scheen A.J. The safety of gliptins: updated data in 2018. Exp Opin Drug Saf 2018; 17 (4): 387-405. doi: 10.1080/14740338.2018.1444027
- Mishriky B.M, Cummings D.M, Tanenberg R.J. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015; 109 (2): 378-88. doi: 10.1016/j.diabres.2015.05.025
- Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64 (5): 562-76. doi: 10.1111/j.1742-1241.2010.02353.x
- Göke B, Gallwitz B, Eriksson J.G et al. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013; 67 (4): 307-16. doi: 10.1111/ijcp.12119
- Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab 2014; 16 (12): 1239-46. doi: 10.1111/dom.12377
- Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet 2012; 380 (9840): 475-83. doi: 10.1016/s0140-6736(12)60691-6
- Matthews D.R, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12 (9): 780-9. doi: 10.1111/j.1463-1326.2010.01233.x.
- Chon S, Gautier J.F. An Update on the Effect of Incretin-Based Therapies on b-Cell Function and Mass. Diabetes Metab J 2016; 40 (2): 99-114. doi: 10.4093/dmj.2016.40.2.99
- Jurczyk A, Diiorio P, Brostowin D et al. Improved function and proliferation of adult human beta cells engrafted in diabetic immunodeficient NOD-scid IL2rγ(null) mice treated with alogliptin. Diabetes Metab Syndr Obes 2013; 6: 493-9. doi: 10.2147/DMSO.S53154
- Lynch C.P, Gebregziabher M, Axon R.N et al. Geographic and racial/ethnic variations in patterns of multimorbidity burden in patients with type 2 diabetes. J Gen Intern Med 2015; 30 (1): 25-32. doi: 10.1007/s11606-014-2990-y
- Pratley R.E, McCall T, Fleck P.R et al. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc 2009; 57 (11): 2011-9. doi: 10.1111/j.1532-5415.2009.02484.x
- Rosenstock J, Wilson C, Fleck P. Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 2013; 15 (10): 906-14. doi: 10.1111/dom.12102
- Karyekar C.S., Ravichandran S, Allen E et al. Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged≥65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 2013; 8: 419-30. doi: 10.2147/CIA.S41246
- Umezawa S, Kubota A, Maeda H et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study. BMC Endocr Disord 2015; 15: 34. doi: 10.1186/s12902-015-0033-2
- White W.B, Cannon C.P, Heller S.R et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-35. doi: 10.1056/NEJMoa1305889
- Mita T, Katakami N, Yoshii H et al. Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A). Diabetes Care 2016; 39 (1): 139-48. doi: 10.2337/dc15-0781
